Главная > Blogs > The Anti-Viral Invention of Virus-Traps Was Disclosed In My German Patent
The Anti-Viral Invention of Virus-Traps Was Disclosed In My German Patent20-01-2014, 22:03. Разместил: admin |
|
The Anti-Viral Invention of Virus-Traps Was Disclosed In My German Patent Application DE19951694 And Is Now Plagiaristically Used By Vecoy Nanomedicines Erez Livneh, CEO and founder of the Israeli company Vecoy Nanomedicines made false statements, that he is inventor of virus-traps Alexander Cherkasky http://feasibilityofalexandercherkaskysinven.blogspot.de/ In the interview with Rivka Borochov (the press release in internet, (Isrtrade), “New Israeli nanotech targets a virus’s Achilles heel”, November 29, 2012, Category: General, Vecoy Nanomedicines has a whole new approach: a virus “decoy” to outwit the world’s worst enemy before it does any damage (By Rivka Borochov)) Livneh said “It’s all(!) in the novelty(!) of what we are doing. While all(!) the current therapies inhibit the viruses within the infected cell, which is a bit too late, we are targeting viruses outside the human cells and are inactivating them before the damage is done.” Thus Livneh made just two false statements, by telling two times the word “all”. The anti-viral idea/strategy, Livneh claims as his own, is not new and not inventive because of my prior invention published as German patent application DE19951694 “Method for Regulation of Expression of Transgenes in Specific Expression Systems, Such As For Example In Immune Cells B, T and Macrophages in vitro and in vivo”, (filed on October 27, 1999 and published on May 3, 2001). In the column 2 (lines 4-17) of DE19951694 is written: “In certain cases, the regulation, i.e. activation or inhibition of expression is not necessary. Thus, an immune cell, such as for example macrophage, NK (natural killer) cells, microglia, T-, B-cell, granulocyte or any other cell, can express CD4, CD155, Adenovirus-receptor or other protein, that will be recognized by viruses(!), and these cells can additionally express anti-viral RNA sequences, such as for example antisense RNA or ribozymes against HIV, polioviral or adenoviral RNA. This expression system builds a trap(!) for viruses, because as soon as a virus recognizes and binds an extracellular domain of a membrane protein, like CD4 or CD155, it (this virus) will be destroyed by the immune cell. The viral RNA will be specifically cleaved (recognized or neutralized) by antiviral antisense RNA or antiviral ribozyme.” The Figure 3 is a symbol/schema for the antiviral trap. In the column 4 (lines 7-19) of DE19951694 is written: “In the Figure 3 is schematically shown the expression system 1. It (this expression system 1) contains the nucleus 2, the gene 21 for CD4, CD155, adenovirus receptor or any other membrane protein, that will be recognized by any virus; the gene 22 for anti-viral RNA 23, expressed CD4, CD155, adenovirus receptor 24 or any other membrane protein, that will be recognized by any virus; and mRNA 25 for the protein 24. The genes are integrated sequence-specifically. Arrows show the migration of proteins or nucleic acids.” This list of numbers and according symbols, especially genes (23) for membrane proteins (24) (that are recognized by viruses), can be found in the columns 5 and 6. The claim 11 of my DE19951694 discloses a macrophage, NK-cell, microglia, B-, T-cell, granulocyte or any other cell(!), that expresses both a. proteins such as for example CD4, CD155, adenovirus receptor and other proteins, that will be recognized by viruses and parallely/additionally, b. antiviral RNA such as for example antisense RNA or ribozymes against HIV, polioviral or adenoviral RNA. Because of my priority and my authorship of this invention of anti-viral traps, Livneh’s statements about Livneh’s “novelty” and “authorship” are false. By doing such false statements, Livneh built and just build false and bewildering basis for making investment decisions. Investors must know these facts, because investors of Vecoy Nanomedicines should have possibilities to reconsider their risks, because the situation regarding protection from competitors have been changed, (because Erez Livneh’s according claim is not novel and not inventive, thus protection from competitors is reduced). Thus Vecoy could be a money-trap. These facts deserve also consideration of possible investors and partners of Vecoy Nanomedicines. Thus Rivka Borochov’s statements “This is not only a novel(!) medical approach, it also addresses one of the largest challenges when it comes to viruses, because they cannot adapt and develop resistance to Vecoy as they do to anti-viral drugs”, “This new(!) type of anti-viral strategy, based on a completely new(!) way of thinking(!), could work to target the worlds’s deadliest viruses, such as HIV, hepatitis B and C and Ebola, as well as others such as the human papillomavirus (HPV) and herpes”, “Although Livneh had a successful career in both academia and later in biotechnology pharmaceutical companies, this idea to create a new(!) way to target viruses came through a lot of research, reading and curiosity”, “An Israeli company hopes to have a new(!) kind of arsenal prepared so that the next big viral war will be an offensive, and not a defensive action”, “Unlike anti-viral injections or drugs that are licensed and on the market, Vecoy is taking a whole new(!) approach to defeating viruses”, “Two hundred years ago when vaccines were first invented, there was a rapid change in managing polio and small pox, two viruses that in the modern world are virtually wiped out. Livneh aspires to be the pioneer(!) who’ll create tomorrow’s solution in the face of possible biological warefare, bio-terrorism and the next SARS or avian flu epidemic” and “ “Viruses are one of the biggest threats to humankind”, says Erez Livneh, the CEO and founder of Vecoy Nanomedicines, the Israeli company that has developed this new(!) weapon to fight viruses” “ are false, because of Vecoy’s claimed antiviral strategy of virus-traps is not novel, not new and not inventive because of my prior description DE19951694. Livneh’s “reading and curiosity” were not sufficient. Before attracting and convincing investors to invest in his firm Vecoy Nanomedicines, Erez Livneh should make secure searches in the data banks for patent literature and he should make true statements. Also the article of Karin Kloosterman “New Israeli tactic makes deadly viruses commit suicide, Vecoy Nanomedicines has a whole new(!) approach: a virus “decoy” to outwit the world’s worst enemy before it does” (published on the blog isrtech.blogspot.de) contains false and bewildering statements, both of the author Karin Kloosterman and of “Israeli biologist Erez Livneh, CEO and founder of a new biotech(!) company Vecoy Nanomedicines.” Kloosterman’s statements “Vecoy offers a cunning new(!) way to disarm viruses(!) by luring(!) them to attack microscopic, cell-like decoys(!). Once inside(!) these traps(!), the viruses effectively commit suicide(!). Livneh presented his(!) invention to colleagues in 2010, when he represented Israel at the multinational program of the Singularity University, based at NASA’s Ames Research base in California. He explained that Vecoy technology(!) can capture(!) and neutralize(!) a wide range of deadly viruses, including resistant strains for which these are no(!) vaccinations or cures(!)”, “While it takes years to come up with new drugs, Vecoy’s(!) virus traps could be tailored to address emerging new viral out breaks quickly and efficiently, even in the event of a bioterror assault. If a government sees a threat coming from an enemy nation or a potential pandemic blowing its way, Vecoy’s(!) solution could potentially inoculate populations before peril arrives”, “While the road is long – at least four or five years to start clinical trials – it is a path be worth taking if these Israeli-made(!) virus decoys can do the job. If Livneh succeeds on his(!) quest, he(!) will no doubt(!) go down in the history books along with Louis Pasteur (for pasteurisation), Sir Alexander Fleming (for penicillin) and Jonas Salk (polio vaccine)”, “Yet all viruses, he (Livneh)(!) notes, have one unchangeable Achilles heel: their cell host recognition site(!) Vecoy uses(!) nanotechnology to give the virus two choices: either latch on the to the Vecoy (!) host trap or mutate in such a way that it cannot penetrate real host cells” and “Besides Ebola and new emerging and highly contagious viruses, Vecoy(!) is also targeting the usual ones many of us struggle with every day, including hepatitis B and C, the human papillomavirus and herpes” are false, because Livneh’s i.e. Vecoy’s described and claimed anti-viral strategy is not novel and not inventive because of my DE19951694 from the year 1999. Livneh’s statements “That is why, in theory, a virus cannot develop adaptive resistance to our(!) traps” and “our(!) virus-traps meet the viruses on their turf, in the bloodstream where they are disarmed before they reach the cells and before the damage is done” are false, because Livneh’s claimed anti-viral technology is not new and not inventive because of my DE19951694 described above. Erez Livneh denied to comment this information. Вернуться назад |